Putney, Inc. Enters the $175M Annual Veterinary NSAID Market
Makes Treatment More Affordable to Pet Owners
Carprofen is widely used in dogs for the relief of pain and inflammation associated with osteoarthritis, as well as the control of post-operative pain associated with soft tissue and orthopedic surgeries. In a recent survey conducted by Advanstar Veterinary Healthcare Communications, 96% of responding veterinarians nationwide indicated they prescribe and dispense branded carprofen medications. Putney’s carprofen caplets have demonstrated bioequivalence to Pfizer’s Rimadyl(R) caplets in an FDA approved study and will be available in the same strengths (25mg, 75mg and 100mg caplets) and convenient packaging as the branded drug.
In the Advanstar survey, 80% of companion animal veterinarians surveyed across the country responded that they would feel comfortable switching to generic carprofen caplets and 88% believe that pet owners are receptive to switching to the generic.
In general, in spite of expired patents on many veterinary drugs, few cost-saving generics have been developed and approved by the FDA for pets. “With carprofen caplets, Putney is delivering a high quality, bioequivalent generic option to veterinarians to help pet owners afford to treat pets,” said
Putney, Inc., is a pharmaceutical company that listens to companion animal veterinarians and responds to their needs — making affordable drugs available, and developing products that address common concerns such as compliance, dosing and palatability. Putney empowers veterinarians with prescribing choices that allow them to pursue the best course of treatment for improved compliance, more satisfied pet owners and happy pets. Learn more at www.putneyvet.com.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
SOURCE Putney, Inc.